Safety and Efficacy of SPARC1203 in Allergic Rhinitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female patients aged 18 to 65 years (both inclusive) with history of seasonal allergic rhinitis and positive skin prick test
History or presence of perennial allergic rhinitis
Upper or lower respiratory tract infection 2 weeks before Visit 2
Significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta-2-agonists alone
Immunizations or vaccinations within 4 weeks prior to Visit 1